Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.32 |
| ▸ | CDC25B | P30305 | 4/20 | 0.32 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.32 |
| ▸ | CDC25A | P30304 | 2/20 | 0.32 |
| ▸ | GLS | O94925 | 1/20 | 0.32 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.31 |
| ▸ | CMA1 | P23946 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25922652 | 0.95 | TMPRSS2 (0.39) | TMPRSS2PTPN1CDC25BPTPN2CDC25A | |
| SCHEMBL30973736 | 0.94 | TMPRSS2 (0.38) | TMPRSS2PTPN1CDC25BPTPN2CDC25A | |
| SCHEMBL30973764 | 0.94 | TMPRSS2 (0.38) | TMPRSS2PTPN1CDC25BPTPN2CDC25A | |
| SCHEMBL30973784 | 0.93 | TMPRSS2 (0.39) | TMPRSS2PTPN1CDC25BPTPN2CDC25A | |
| SCHEMBL27413367 | 0.93 | TMPRSS2 (0.38) | TMPRSS2PTPN1CDC25BPTPN2CDC25A | |
| SCHEMBL24916999 | 0.93 | TMPRSS2 (0.38) | TMPRSS2PTPN1CDC25BPTPN2CDC25A | |
| SCHEMBL30973730 | 0.93 | TMPRSS2 (0.39) | TMPRSS2PTPN1CDC25BPTPN2CDC25A | |
| SCHEMBL30973779 | 0.93 | TMPRSS2 (0.38) | TMPRSS2PTPN1CDC25BPTPN2CDC25A | |
| SCHEMBL30973744 | 0.92 | TMPRSS2 (0.37) | TMPRSS2PTPN1CDC25BPTPN2CDC25A | |
| SCHEMBL27413244 | 0.92 | TMPRSS2 (0.37) | TMPRSS2PTPN1CDC25BPTPN2CDC25A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12102648-B2 | Orally-bioavailable nucleoside analogs | VenatoRx Pharmaceuticals, Inc. (US) | 2024-10-01 | — | — | US | disclosed |
| EP-4355755-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | Venatorx Pharmaceuticals, Inc. (US) | 2024-04-24 | — | — | EP | disclosed |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | VenatoRx Pharmaceuticals, Inc. (US) | 2023-05-02 | — | — | US | disclosed |
| US-20230024722-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-01-26 | — | — | US | disclosed |
| US-20230024722-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-01-26 | — | — | US | disclosed |
| WO-2022265964-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. (US) | 2022-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024722-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | TMPRSS2 100/4885PTPN1 4791/4885CDC25B 2613/4885 |
| US-12102648-B2 | Orally-bioavailable nucleoside analogs | SLC29A2, SLC29A1, PNP | TMPRSS2 100/4885PTPN1 4791/4885CDC25B 2613/4885 |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | SLC29A2, SLC29A1, PNP | TMPRSS2 100/4885PTPN1 4791/4885CDC25B 2613/4885 |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | TMPRSS2 100/4885PTPN1 4791/4885CDC25B 2613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.